| General Information | |
|---|---|
| ZINC ID | ZINC000096906001 |
| Molecular Weight (Da) | 343 |
| SMILES | CCCCn1cc(Cc2cccc3ccccc23)c2cccc(OC)c21 |
| Molecular Formula | C24N1O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 106.446 |
| HBA | 1 |
| HBD | 0 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 26 |
| LogP | 6.297 |
| Activity (Ki) in nM | 10.965 |
| Polar Surface Area (PSA) | 14.16 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | + |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | + |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | + |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.094 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 19 |
| Fraction csp3 | 0.25 |
| Ilogp | 3.83 |
| Xlogp3 | 6.33 |
| Wlogp | 6.19 |
| Mlogp | 4.53 |
| Silicos-it log p | 6.12 |
| Consensus log p | 5.4 |
| Esol log s | -6.1 |
| Esol solubility (mg/ml) | 0.000271 |
| Esol solubility (mol/l) | 0.00000079 |
| Esol class | Poorly sol |
| Ali log s | -6.42 |
| Ali solubility (mg/ml) | 0.000131 |
| Ali solubility (mol/l) | 0.00000038 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.75 |
| Silicos-it solubility (mg/ml) | 0.00000061 |
| Silicos-it solubility (mol/l) | 1.78E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -3.9 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 1 |
| Synthetic accessibility | 2.85 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -7.038 |
| Logd | 4.894 |
| Logp | 6.356 |
| F (20%) | 0.961 |
| F (30%) | 0.98 |
| Mdck | 1.39E-05 |
| Ppb | 0.9828 |
| Vdss | 2.229 |
| Fu | 0.0056 |
| Cyp1a2-inh | 0.545 |
| Cyp1a2-sub | 0.82 |
| Cyp2c19-inh | 0.883 |
| Cyp2c19-sub | 0.164 |
| Cl | 9.696 |
| T12 | 0.1 |
| H-ht | 0.164 |
| Dili | 0.935 |
| Roa | 0.16 |
| Fdamdd | 0.619 |
| Skinsen | 0.209 |
| Ec | 0.003 |
| Ei | 0.884 |
| Respiratory | 0.748 |
| Bcf | 2.297 |
| Igc50 | 5.141 |
| Lc50 | 6.471 |
| Lc50dm | 6.294 |
| Nr-ar | 0.273 |
| Nr-ar-lbd | 0.006 |
| Nr-ahr | 0.335 |
| Nr-aromatase | 0.81 |
| Nr-er | 0.561 |
| Nr-er-lbd | 0.77 |
| Nr-ppar-gamma | 0.126 |
| Sr-are | 0.686 |
| Sr-atad5 | 0.075 |
| Sr-hse | 0.474 |
| Sr-mmp | 0.636 |
| Sr-p53 | 0.579 |
| Vol | 385.493 |
| Dense | 0.89 |
| Flex | 0.286 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 4 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 2 |
| Qed | 0.407 |
| Synth | 2.135 |
| Fsp3 | 0.25 |
| Mce-18 | 20 |
| Natural product-likeness | -0.442 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Rejected |
| Goldentriangle | Accepted |